ESALF Company Profile and Key Details

Q: Who are the executives of ESALF?

Dr. Lynn D. Kramer FAAN, M.D.Vice President & Chief Clinical Officer - Alzheimer's Disease and Brain HealthMr. Haruo NaitoChief Executive Officer, Representative Corporation Officer & DirectorMs. Sayoko SasakiVice President of Corporation Communications & ESGDr. Nadeem Sarwar Ph.D.PresMr. Teruyuki MasakaVice President & Chief HR OfficerMr. Yosuke AkitaVice President, Chief Compliance Officer & Chief Information Security OfficerMr. Tatsuyuki YasunoSenior Vice President, Chief Financial Officer & Chief IR OfficerMr. Yasushi OkadaRepresentative Corporation Officer, Chief Operating Officer, Industry Affairs, China Bus. & Data IntegrityMr. Kenta TakahashiExecutive Vice President of IP, Internal Audit & Control, Gen. Counsel and Chief Compliance OfficerMitsuru ShomonVice President, Chief Financial Officer and Head of Corporation Fin. & Accounting HQsMr. Masatomi AkanaChief Gov. Rel. and IR Officer, SVice President of Global Value, Acc., Japan Subs, Gen., Env. & Safety Aff.Mr. Gary HendlerSenior Vice President & Pres of EMEA RegionMs. Yanhui FengSenior Vice President

OTC : ESALF

Eisai Co

$27.19

-2.81-9.37%

Open: 4:00 PM

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Eisai Co., Ltd. (ESALF) stock declined over -9.37%, trading at $27.19 on OTC, down from the previous close of $30.00. The stock opened at $27.19, fluctuating between $27.19 and $33.00 in the recent session.

Stock Snapshot

Prev. Close

7.67B

Market Cap

27.19

Day Low

24.28

P/E Ratio

1.12

EPS (TTM)

166.26

Cash Flow per Share

27.19

Open

282.11M

Number of Shares

Day High

94.45%

Free Float in %

2855.22

Book Value

966

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Mar 09, 2026	30.60	30.60	30.60	30.60	230
Feb 18, 2026	33.00	33.00	33.00	33.00	966
Jan 26, 2026	31.68	31.68	26.76	26.76	275
Jan 21, 2026	28.50	28.50	28.50	28.50	200
Jan 20, 2026	27.00	27.00	27.00	27.00	118
Jan 14, 2026	30.61	30.61	30.61	30.61	130
Jan 13, 2026	30.00	30.00	30.00	30.00	140
Jan 12, 2026	31.50	31.50	31.50	31.50	105
Jan 07, 2026	30.00	30.00	30.00	30.00	10
Jan 06, 2026	32.00	32.00	32.00	32.00	200
Dec 31, 2025	29.73	29.73	29.73	29.73	500
Dec 29, 2025	30.00	30.00	30.00	30.00	1.03K
Dec 23, 2025	26.71	29.00	26.71	29.00	265
Dec 17, 2025	28.68	28.68	28.55	28.55	275
Dec 03, 2025	30.00	30.00	30.00	30.00	200
Dec 02, 2025	29.25	29.25	29.25	29.25	17
Nov 21, 2025	27.40	27.40	27.40	27.40	510
Nov 18, 2025	29.68	29.71	29.68	29.69	494
Nov 17, 2025	32.52	32.52	32.52	32.52	2
Nov 13, 2025	31.42	31.42	29.33	29.33	195

Contact Details

Tokyo, 112-8088

Japan

https://www.eisai.co.jp 813 381 73700

About Company

Eisai Co., Ltd. offers pharmaceutical products in Japan. It offers Aricept for the treatment of alzheimer's disease/dementia with Lewy bodies; Methycobal for the treatment of peripheral neuropathy; and Fycompa, an antiepileptic drug for the adjunctive treatment of partial-onset and primary generalized tonic-clonic seizures. The company also provides Lyrica for pain treatment; Dayvigo, an anti-insomnia drug for the treatment of adults with insomnia; Lenvima, an anticancer agent/molecular targeted medicine for the treatment of thyroid cancer, renal cell carcinoma in combination with everolimus, and hepatocellular carcinoma; and Halaven, an anticancer agent/microtubule dynamics inhibitor for the treatment of breast cancer and liposarcoma. In addition, it offers Pariet, a proton-pump inhibitor for the treatment of gastric and duodenal ulcers, reflux esophagitis, and eradication of Helicobacter pylori infections, etc.; Humira, a fully human anti-TNF-a monoclonal antibody for the treatment of autoimmune diseases, such as rheumatoid arthritis; and Chocola BB plus, a vitamin B2 preparation for rough skin and stomatitis, as well as various products, which include third-class OTC drugs, designated quasi-drugs, and food with nutrient function. The company was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955. Eisai Co., Ltd. was incorporated in 1941 and is headquartered in Tokyo, Japan.

Stock Peers

MKGAF

-6.5-3.38%

MERCK Kommanditgesellschaft auf Aktien$186.00 HKMPY

-0.87-1.69%

Hikma Pharmaceuticals PLC$50.66 SGIOF

Shionogi & Co., Ltd.$43.89 MKKGY

-0.85-2.24%

MERCK Kommanditgesellschaft auf Aktien$37.11 IPSEY

Ipsen S.A.$33.00 TKPHF

Takeda Pharmaceutical Company Limited$26.83 TEVJF

5.26+43.91%

Teva Pharmaceutical Industries Limited$17.24 APNHY

Aspen Pharmacare Holdings Limited$12.52 TAIPY

Taisho Pharmaceutical Holdings Co., Ltd.$12.00 GTBIF

-0.38-3.20%

Green Thumb Industries Inc.$11.49

Company Overview

Eisai Co., Ltd. (OTC:ESALF) closed at $27.19 USD, losing -$2.81 (-9.37%) from the previous close of $30.00. The stock is currently mid-range between its 52-week high and low $24.51 and $35.83. With a market capitalization of about $7.67 billion, Eisai Co., Ltd. is classified as a mid-cap and shows lower-than-market volatility (beta ~-0.11). Key stats such as the average daily volume over the past year has been around 73.00 shares, trading with heavier-than-usual volume. Headquartered in Tokyo, None, Eisai Co., Ltd. operates in the Healthcare sector and the Drug Manufacturers - Specialty & Generic industry. Led by CEO Haruo Naito, the company employs approximately 11,067 people and listed since April 07, 2011. Eisai Co., Ltd. offers pharmaceutical products in Japan.

Valuation Metrics

Eisai Co., Ltd. trades at a P/E ratio of 34.07, slightly above the S&P 500 average, with a price-to-sales ratio of 1.82 and a price-to-book ratio of 1.64 suggesting the stock is closer to book value. The P/FCF stands at 20.21, also above market averages.

Dividend & Fair Value

Eisai Co., Ltd. last paid a dividend of 1 per share, this equals a trailing yield of roughly inf%. Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $22.43. This means the shares are trading above this model’s fair value.

Earnings & Analyst Outlook

Eisai Co., Ltd. earnings surprise history is a mixed track record. The quarter that ended February 09, 2026, missed forecasts by -17.1%. The prior quarter beat by -26.27%. Over the last six quarters, Apple has recorded several small beats. These include -81.13% in May 12, 2025.

Financial & Profitability Overview

Over the trailing twelve months, Eisai Co generated $789.40B in revenue, or $2.78K per share. Gross margin was 78.62%, operating margin 5.19%, and net profit margin 5.88%. Returns are modest, with ROA at 3.35% and ROE at 5.52%.
On valuation metrics, Eisai Co trades at a P/E of 34.07, P/S of 1.82 and P/B of 1.64. The current ratio is 2.17 and quick ratio is 1.54. Operationally, the company’s inventory turnover is 0.74 and cash conversion cycle is 434.78 days. Debt-to-equity is 0.26, supported by a cash flow-to-debt ratio of 0.37.

Quarterly Financial Highlights

For the quarter ended Mar 31, 2025, Eisai Co posted revenue of $789.40B, down slightly from $741.75B in the prior quarter. Gross profit was $620.59B (margin 78.62%). Operating income was $40.98B (margin 5.2%). Net income was$46.43B (EPS $163.76).
The company ended the quarter with $265.56B in cash and short-term investments, a total debt of $187.52B, and net debt of - $78.04B. Total assets were $1.39T, with equity of $865.97B. Financials further reflected stability, with operating cash flow of $30.12B, free cash flow of $18.18B, and capital expenditures of - $11.93B.

Price Forecast & Outlook

Our AI price prediction model suggests that Eisai Co., Ltd. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term.

Key Takeaways

Valuation shows Eisai Co., Ltd. trading at a premium to the broader market with a P/E of 34.07.

Frequently Asked Questions

What is the current Eisai Co., Ltd. (ESALF) stock price?

Eisai Co., Ltd. (OTC: ESALF) stock price is $27.19 in the last trading session. During the trading session, ESALF stock reached the peak price of $33.00 while $27.19 was the lowest point it dropped to. The percentage change in ESALF stock occurred in the recent session was -9.37% while the dollar amount for the price change in ESALF stock was - $2.81.

ESALF's industry and sector of operation?

The OTC listed ESALF is part of Drug Manufacturers - Specialty & Generic industry that operates in the broader Healthcare sector. Eisai Co., Ltd. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of ESALF?

Dr. Lynn D. Kramer FAAN, M.D.
Vice President & Chief Clinical Officer - Alzheimer's Disease and Brain Health
Mr. Haruo Naito
Chief Executive Officer, Representative Corporation Officer & Director
Ms. Sayoko Sasaki
Vice President of Corporation Communications & ESG
Dr. Nadeem Sarwar Ph.D.
Pres
Mr. Teruyuki Masaka
Vice President & Chief HR Officer
Mr. Yosuke Akita
Vice President, Chief Compliance Officer & Chief Information Security Officer
Mr. Tatsuyuki Yasuno
Senior Vice President, Chief Financial Officer & Chief IR Officer
Mr. Yasushi Okada
Representative Corporation Officer, Chief Operating Officer, Industry Affairs, China Bus. & Data Integrity
Mr. Kenta Takahashi
Executive Vice President of IP, Internal Audit & Control, Gen. Counsel and Chief Compliance Officer
Mitsuru Shomon
Vice President, Chief Financial Officer and Head of Corporation Fin. & Accounting HQs
Mr. Masatomi Akana
Chief Gov. Rel. and IR Officer, SVice President of Global Value, Acc., Japan Subs, Gen., Env. & Safety Aff.
Mr. Gary Hendler
Senior Vice President & Pres of EMEA Region
Ms. Yanhui Feng
Senior Vice President

How ESALF did perform over past 52-week?

ESALF's closing price is 14.57% higher than its 52-week low of $24.51 where as its distance from 52-week high of $35.83 is -41.3%.

How many employees does ESALF have?

Number of ESALF employees currently stands at 11,067.

Link for ESALF official website?

Official Website of ESALF is: https://www.eisai.co.jp

How do I contact ESALF?

ESALF could be contacted at phone 813 381 73700 and can also be accessed through its website. ESALF operates from 4-6-10, Koishikawa, Tokyo, 112-8088, Japan.

How many shares of ESALF are traded daily?

ESALF stock volume for the day was 966 shares. The average number of ESALF shares traded daily for last 3 months was 73.

What is the market cap of ESALF currently?

The market value of ESALF currently stands at $7.67B with its latest stock price at $27.19 and 282.11M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	11067
Beta	-0.19
Sales or Revenue	$789.40B
5Y Sales Change%	0.147%
Fiscal Year Ends	March
Sector	Healthcare
Industry	Drug Manufacturers - Specialty & Generic

ESALF Company Profile and Key Details

Eisai Co

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Earnings & Analyst Outlook

Dividend & Fair Value

Financial & Profitability Overview

Quarterly Financial Highlights

Company Overview

Valuation Metrics

Price Forecast & Outlook

Key Takeaways